Je was op zoek naar: open label study (Engels - Maltees)

open label extension study
studju ta’ estensjoni open-label

(open-label)
(kemm l

study 4: open-label extension study
studju 4: studju ta’ estensjoni open-label

open-label period
perjodu open-label

open-label uncontrolled extension study in adults
studju ta' estensjoni mhux ikkontrollat open-label fl-adulti

in the open-label study there was no difference in
fl -

is controlled studies and one was an open-label study.
riz alfa, beta u darbepoetin alfa, li kienu jinvolvu total ta ’ 2, 833 pazjent, li erba ’ minnhom kienu studji double- blind u kkontrollati bil- plaċebo, u wieħed kien studju open- label.

open-label extension period
perjodu ta’ estensjoni open label

study enb-009-10 was an open-label, randomised study.
studju enb-009-10 kien open-label, u studju li fih il-parteċipanti jintgħażlu b’mod każwali.

open-label phase 1 dose-escalation study (mdx1106-03)
studju b’doża li togħla ta’ fażi 1 open-label (mdx106-03)

single-arm open-label studies
studji single- arm open- label

long-term, open label extension studies
studji ta’ estenzjoni fit-tul open label

the data are from an open-label study and no firm conclusions can be drawn.
id-dejta hija minn studju open-label u ma jistgħux jittieħdu konklużjonijiet definiti.

in the open-label study there was no difference in overall survival between patients treated a
għal tnejn mill- istudji ntagħżlu pazjenti li kien qed jiġu kkurati bil- kimoterapija.

therefore the studies were performed as open-label studies.
għalhekk l-istudji saru bit-tikketta tidher.

open-label, uncontrolled, extension studies in paediatric patients
studji ta' estensjoni, mhux ikkontrollati, b'tikketta mikxufa f'pazjenti pedjatriċi

to date, there are limited amount of data from an open label study on long term efficacy of wakix in this indication.
sal-lum, hemm ammont limitat ta' dejta minn studju open label fuq l-effikaċja fit-tul ta' wakix f'din l-indikazzjoni.

the phase 2 portion of the study was a randomised, open label study of olaratumab plus doxorubicin versus doxorubicin alone.
il-proporzjon ta’ fażi 2 tal-istudju fejn kemm l-investigaturi kif ukoll l-individwi li ntagħżlu b’mod arbitrarju kienu jafu liema sustanza qed tintuża kien studju ta’ olaratumab flimkien ma’ doxorubicin versus doxorubicin waħdu.

in the phase iib, open-label study (c209), 6.9% (16/233) patients died.
fl-istudju (c209) ta’ fażi iib, tikketta li tingħaraf, 6.9% (16/233) tal-pazjenti mietu.

abatacept was evaluated in an open-label study in rheumatoid arthritis patients administered the 23- valent pneumococcal vaccine.
abatacept ġie evalwat fi studju open-label f’pazjenti b’artrite rewmatojde li ngħataw it-tilqima pnewmokokkali ta’ 23 valent.